Gefitinib Eugia

Gefitinib Eugia is an oral medication used to target specific proteins in cancer cells. It is commonly prescribed for certain types of lung cancer. This medication is manufactured by Eugia Pharma (Malta) Ltd.

Gefitinib Eugia is primarily used in the treatment of non-small cell lung cancer (NSCLC). It works by targeting specific proteins that are involved in the growth and spread of cancer cells. This medication is often prescribed for patients with specific genetic mutations that make their cancer cells dependent on these proteins for growth.

Common effects of Gefitinib Eugia may include skin rash, diarrhea, and dry skin. Some users may also experience nausea, vomiting, and loss of appetite. These effects can vary in severity and may not affect everyone who takes the medication.

Gefitinib Eugia should be handled with care and stored as directed. It is important to inform your healthcare provider about any other medications you are taking to avoid potential interactions. This medication should be used under the supervision of a healthcare professional.

Gefitinib Eugia may interact with certain medications, including those that are metabolized by the liver. It is important to discuss all current medications with your healthcare provider before starting Gefitinib Eugia. Avoiding alcohol and other substances that may affect liver function is also recommended.